

About IntelGenx Corp.

IntelGen_x Corp.

Founded in June 2003, IntelGenx Technologies Corp. ("IntelGenx") is a Montreal-based drug delivery company focused on novel oral controlled release technologies. IntelGenx has developed three proprietary platform technologies, a Tri-Layer Tablet "VersaTab", a Mucoadhesive Tablet "AdVersa", and a Quick Release Wafer "VersaFilm", which enable the company to customize the release profile of orally administered drugs and maximize their therapeutic effect.


www.intelgenx.com

Corporate Info

Symbol: (OTCBB:IGXT; TSX-V:IGX)
Shares Outstanding:
- Basic: 33.1 million
- Fully Diluted: 49.5 million
Recent Share Price: \$0.50

Technologies

Tri-Layer technology "VersaTab" represents a new generation of controlled release tablets that uses a layering technique to modulate the release of active compounds. The technology is based on a Tri-Layer tablet with an active core layer and two erodible cover layers.



- Superior alternative to osmotic pump delivery systems
- Broad range of delivery profiles
- Significant manufacturing cost savings

Quick Release Wafer technology "VersaFilm" is the application system of choice for indications requiring rapid onset of action like migraine, motion sickness and nausea.



- Instant release of drug
- Bypasses GI tract, advantageous for drugs having GI side effects
- Avoids/reduces first-pass metabolism
- Ideal for lifecycle management
- FDA approved for pharmaceutical products

Mucoadhesive tablet technology "AdVersa" provides controlled release of actives to the oral mucosa and is intended for molecules having a high first pass effect upon conventional oral administration.



- Intended for buccal or sublingual delivery
- Variable residence time - immediate or slow release of the drug
- Release of the drug not requiring mastication or water

Recent Highlights

[04/21/2010](#)

IntelGenx Announces Licensing of Anti-Migraine Film Product

[03/10/2010](#)

IntelGenx Granted Bupropion Patent

[03/04/2010](#)

IntelGenx and Cannasat Announce Letter of Intent for Relivar License

[01/25/2010](#)

IntelGenx Enters Strategic Manufacturing Partnership for VersaFilm Technology

Management

Dr. Horst Zerbe, Ph.D.
Chairman and CEO

Paul A. Simmons, AFCA
Chief Financial Officer

James Wittenberg, R.Ph., MS.
SVP, Business Development

Nadine Paiement, M.Sc.
Director, R & D

Directors

Dr. Horst G. Zerbe
Chairman and CEO, IntelGenx

Ian Troup, B.Sc.

Bernd J. Melchers, CFA

J. Bernard Boudreau, QC, PC

Product Pipeline

● 505(b)(2)

Product	Platform	Preclinical Development	Phase 1	Phase 2/3	NDA	Commercial Launch	
Prenatal Vitamin	VersaTab	Launched Nov. 2008					
Antidepressant ●	VersaTab	NDA filed Q1/2009					H1/11
Antihypertensive	VersaTab	Pilot Biostudy Compl.					H2/12
Osteoarthritis	VersaTab						TBD
Cholesterol Reduction ●	VersaTab	Pilot Biostudy Compl.					TBD
Schizophrenia ●	AdVersa	Project on hold					TBD
Neuropathic Pain ●	AdVersa	Pilot Biostudy Compl.					H2/12
Erectile Dysfunction ●	VersaFilm						H1/12
Anti-Migraine ●	VersaFilm	Pilot Biostudy compl.					Q1/12
IBS/Diarrhea ●	VersaFilm						H2/12

Upcoming Milestones

- Q2, 2010 Complete pilot study for ED film
- Q2, 2010 Meet with FDA for CRL response
- Q3, 2010 Complete pivotal migraine study
- Q3/Q4, 2010 Respond to FDA CRL letter
- Q4, 2010 File ANDA antihypertensive product
- Q1, 2011 Approval of CPI-300 NDA

Contact Info

IntelGenx Corp.

6425 Abrams, St-Laurent (Qc) H4S 1X9
 Telephone: 514-331-7440
 Fax: 514-331-0436
 E-mail: info@intelgenx.com

Investor Relations - Canada

Hogan Mullally
 SectorSpeak Inc.
 Winnipeg, Manitoba
 Tel: 204-479-2516
 hogan@sectorspeak.com

Investor Relations - USA

Jeffrey Benison
 Little Gem Life Science Partners
 New York, NY
 Tel: 212-334-8709
 jeffrey@littlegem.us

Investment Highlights

- Unique disruptive drug delivery platform technologies
- Patented technology and strong IP portfolio
- Broad product pipeline
- First product commercialized 11/2008
- Addressing multi-billion dollar markets
- Strong management and key scientific expertise
- Strategic R&D and commercial partnerships in place

Delivering Technology to the Pharmaceutical Industry

IntelGenx Corp.